£490.00

The 2023-2028 Outlook for Intravenous Immunoglobulin for Guillain-Barre Syndromes for US Zip Codes

Subjects

Price data last checked 27 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£490 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 64 days · 64 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 64 days • 1 price levels

Days at Price

Price Analysis

Most common price: £490 (64 days, 100.0%)

Price range: £490 - £490

Price levels: 1 different prices over 64 days

Description

This study covers the latent demand outlook for intravenous immunoglobulin for guillain-Barre syndromes across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for intravenous immunoglobulin for guillain-Barre syndromes. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of intravenous immunoglobulin for guillain-Barre syndromes as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Akari Therapeutics, Biotest, China Biologic Products Holdings, CSL Behring, Grifols, Kedrion, Nihon Pharmaceutical Company, Octapharma, and Shire. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BST822SP
Category: Books > Subjects
Domain: Amazon UK
Release Date: 09 January 2023
Listed Since: 27 January 2023

The 2023-2028 Outlook for Intravenous Immunoglobulin for Guillain-Barre Syndromes for US Zip Codes

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics for US Zip Codes

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in China

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in Japan

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in India

The 2023-2028 World Outlook for Guillain-Barre Syndrome Therapeutics

The 2023-2028 Outlook for Immunoglobulin Diagnostic Tests in India

The 2023-2028 Outlook for Intravenous Therapy and Vein Access for US Zip Codes

The 2023-2028 Outlook for Enzyme Replacement Therapy for Gaucher Diseases for US Zip Codes

The 2013-2018 Outlook for Lou Gehrig's Disease Drugs in India

The 2023-2028 Outlook for Immunoglobulin Plasma Therapeutics in the United States

The 2013 Import and Export Market for Glycosides, Glands or Other Organs and Extracts, Antisera, Vaccines, and Similar Products in Bulgaria

The 2023-2028 Outlook for COVID-19 Vaccines for US Zip Codes

The 2023-2028 Outlook for Intravenous Therapy and Vein Access in Japan

The 2013 Import and Export Market for Lysine, Its Esters and Salts Thereof, and Glutamic Acid and Its Salts in the United Kingdom

The 2013 Import and Export Market for Glycosides, Glands or Other Organs and Extracts, Antisera, Vaccines, and Similar Products in France

The 2013-2018 Outlook for In-Game Advertising (IGA) in Latin America

Immunotherapies for Neurologic Diseases (Volume 214) (Handbook of Clinical Neurology, Volume 214)

The 2023-2028 Outlook for Myasthenia Gravis in India

The 2023-2028 Outlook for In Vitro Diagnostics for US Zip Codes

The 2013-2018 Outlook for In-Game Advertising (IGA) in North America & the Caribbean

The 2023-2028 Outlook for Enzyme Replacement Therapy for Gaucher Diseases in the United States

The 2023-2028 Outlook for Gram-Positive Bacterial Infections in India

The 2013-2018 Outlook for In-Game Advertising (IGA) in the United States

The 2013 Import and Export Market for Natural or Synthetic Glycosides and Their Salts, Ethers, Esters, and Other Derivatives in the United Kingdom